The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Somatostatin receptor antagonists for imaging and therapy.
Open accessAbstract
Somatostatin receptor (sstr) scintigraphy for imaging and sstr analogs for treatment have been used for more than 20 y. An important improvement in recent years was the introduction of peptide receptor radionuclide therapy with radiolabeled sstr agonists, such as [90Y-DOTA0,Tyr3]octreotide or [177Lu-DOTA0,Tyr3]octreotide (90Y- or 177Lu-DOTATOC, respectively) and [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE). PET/CT with 68Ga-labeled sstr agonists, such as 68Ga-DOTATOC, 68Ga-DOTATATE, and [68Ga-DOTA,1-Nal3]octreotide (68Ga-DOTANOC), plays an important role in staging and restaging neuroendocrine tumors. Most importantly, sstr scintigraphy and sstr PET/CT can distinguish patients who will qualify for and benefit from peptide receptor radionuclide therapy. This characteristic of sstr targeting is important because it allows a personalized treatment approach (theranostic approach). Until recently, it was thought that internalization of the radiolabeled agonist was mandatory for sstr-mediated imaging and therapy. It was Ginj et al. who proposed in 2006 the paradigm shift that radiolabeled sstr antagonists may perform better than agonists despite the lack of internalization. Despite the rather limited number of head-to-head comparisons of sstr antagonists and agonists, the superiority of sstr antagonists was demonstrated in several cases. From a small library of sstr antagonists, the analog JR11 (Cpa-c[d-Cys-Aph(Hor)-d-Aph(Cbm)-Lys-Thr-Cys]-d-Tyr-NH2), an antagonist with selectivity for sstr subtype 2, showed the best overall characteristics for sstr subtype 2 targeting and was therefore selected for clinical translation. JR11 is under clinical development as a PET imaging agent when labeled with 68Ga (68Ga-NODAGA-JR11 or 68Ga-OPS202) and as a therapeutic agent when labeled with 177Lu (177Lu-DOTA-JR11 or 177Lu-OPS201). In this article, we discuss the development and current status of radiolabeled sstr antagonists. Evidence based on preclinical work, on quantitative in vivo autoradiography of human tumor slices, and on human data now supports a shift to sstr antagonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Taking the proposed mechanism, preclinical and clinical studies into consideration, it is obvious that using radiolabeled SSTR antagonists, especially LM3 and JR11, may provide more successful imaging and PRRT strategies for neuroendocrine tumors, even those with relatively low SSTR expression (130, 137, 141) compared to agonists.”
From Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists (2022) · cites this paper as [141]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Reubi, J. C., Schär, J.-C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., & Mäcke, H. R. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050034 · Cited by 1,127
Pavel, M. E., O’Toole, D., Costa, F. P., Capdevila, J., Gross, D., Kianmanesh, R., Krenning, E. P., Knigge, U., Salazar, R., Pape, U., et al. (2016) · Neuroendocrinology · doi:10.1159/000443167 · Cited by 1,038
Ginj, M., Zhang, H., Waser, B., Cescato, R., Wild, D., Wang, X., Érchegyi, J., Rivier, J., Mäcke, H. R., & Reubi, J. C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607761103 · Cited by 526
Antunes, P., Ginj, M., Zhang, H., Waser, B., Baum, R. P., Reubi, J. C., & Maëcke, H. R. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0317-x · Cited by 395
Wild, D., Fani, M., Fischer, R., Pozzo, L. D., Kaul, F., Krebs, S. S., Fischer, R., Rivier, J., Reubi, J. C., Maëcke, H. R., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.138834 · Cited by 267
Fani, M., Pozzo, L. D., Abiraj, K., Mansi, R., Tamma, M. L., Cescato, R., Waser, B., Weber, W., Reubi, J. C., & Maëcke, H. R. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.087999 · Cited by 264
Radiopeptide Imaging and Therapy in Europe
Ambrosini, V., Fani, M., Fanti, S., Forrer, F., & Maëcke, H. R. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.085753 · Cited by 201
First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible
Wild, D., Fani, M., Béhé, M. P., Brink, I., Rivier, J., Reubi, J. C., Maëcke, H. R., & Weber, W. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.088922 · Cited by 184
Unexpected Sensitivity of sst2 Antagonists to N-Terminal Radiometal Modifications
Fani, M., Braun, F., Waser, B., Beetschen, K., Cescato, R., Erchegyi, J., Rivier, J. E., Weber, W. A., Maecke, H. R., & Reubi, J. C. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.102764 · Cited by 172
Self-citation
Flagged first, then by citations
1 of the 24 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Nicolas, 2015, Wider safety window with radiolabeled somatostatin receptor antagonists over agonists [abstract], J Nucl Med., 56, 335
Cited by
Sorted by citations
Items 101–200 of 274
Structural modifications of amino acid sequences of radiolabeled peptides for targeted tumor imaging
Maleki, F., Farahani, A. M., Rezazedeh, F., & Sadeghzadeh, N. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103802 · Cited by 17
Vahidfar, N., Farzanehfar, S., Abbasi, M., Mirzaei, S., Delpassand, E. S., Abbaspour, F., Salehi, Y., Biersack, H. J., & Ahmadzadehfar, H. (2022) · Cancers · doi:10.3390/cancers14081914 · Cited by 19
Kaloudi, A., Kanellopoulos, P., Radolf, T., Chepurny, O. G., Rouchota, M. G., Loudos, G. K., Andreae, F., Holz, G. G., Nock, B. A., & Μάινα, Θ. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00605 · Cited by 16
Meester, E. J., de Blois, E., Krenning, B. J., van der Steen, A. F. W., Norenberg, J. P., van Gaalen, K., Bernsen, M. R., de Jong, M., & der Heiden, K. V. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00772-z · Cited by 16
Ciobanu, O., Martin, S. C., & Fica, S. V. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10914 · Cited by 18
Effectiveness of [67Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer
Ketchemen, J. P., Njotu, F. N., Babeker, H., Ahenkorah, S., Tikum, A. F., Nwangele, E., Henning, N. W., Cleeren, F., & Fonge, H. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06648-3 · Cited by 19
Periferakis, A., Tsigas, G., Periferakis, A.-T., Tone, C. M., Hemes, D. A., Periferakis, K., Troumpata, L., Bădărău, I. A., Scheau, C., Căruntu, A., et al. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46090578 · Cited by 16
Ebbehøj, A. L., Iversen, P., Kramer, S., Stochholm, K., Poulsen, P. L., Hjorthaug, K., & Søndergaard, E. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae764 · Cited by 16
Shaheen, S., Moradi, F., Gamino, G., & Kunz, P. L. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-0711-9 · Cited by 16
Somatostatin receptor radionuclide therapy in neuroendocrine tumors
Haider, M., Das, S., Al‐Toubah, T., Pellè, E., El-Haddad, G. E., & Strosberg, J. (2021) · Endocrine Related Cancer · doi:10.1530/erc-20-0360 · Cited by 16
Receptory somatostatynowe w mózgu
Kossut, M. M., Łukomska, A., Dobrzański, G., & Liguz‐Lecznar, M. (2018) · Postępy Biochemii · doi:10.18388/pb.2018_133 · Cited by 14
Kanellopoulos, P., Nock, B. A., Greifenstein, L., Baum, R. P., Roesch, F., & Μάινα, Θ. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314590 · Cited by 15
Imaging inflammation in atherosclerotic plaques, targeting SST2 with [111In]In-DOTA-JR11
Meester, E. J., Krenning, B. J., de Blois, E., de Jong, M., van der Steen, A. F. W., Bernsen, M. R., & der Heiden, K. V. (2020) · Journal of Nuclear Cardiology · doi:10.1007/s12350-020-02046-y · Cited by 15
[18F]FET-βAG-TOCA: The Design, Evaluation and Clinical Translation of a Fluorinated Octreotide
Allott, L., Dubash, S., & Aboagye, E. O. (2020) · Cancers · doi:10.3390/cancers12040865 · Cited by 15
Liu, M., Ren, C., Zhang, H., Zhang, Y., Huang, Z., Jia, R., Cheng, Y., Bai, C., Xu, Q., Zhu, W., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06790-y · Cited by 14
Current and future directions in theranostics for neuroendocrine prostate cancer
Bilgin, G. B., Lucien, F., Chaudhuri, A. A., Orme, J. J., Childs, D. S., Muniz, M., Li, G. G., Chauhan, P. S., Lee, S., Gupta, S., et al. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102941 · Cited by 14
Recent Progress in Peptide-Based Fluorescent Probes Biomedical Applications: A Review
Zhong, X., Xie, Y., Chen, Y., Lu, Y., & Hou, M. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s529323 · Cited by 13
Şen, F., Sheikh, G. T., von Hinten, J., Schindele, A., Kircher, M., Dierks, A., Pfob, C. H., Serfling, S. E., Buck, A. K., Pelzer, T., et al. (2023) · Cancers · doi:10.3390/cancers15143595 · Cited by 13
Kleynhans, J., Ebenhan, T., Cleeren, F., & Sathekge, M. M. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06719-5 · Cited by 13
Rozenblum, L., Mokrane, F., Yeh, R., Sinigaglia, M., Besson, F. L., Seban, R., Chougnet, C., Revel-Mouroz, P., Zhao, B., Otal, P., et al. (2019) · Abdominal Radiology · doi:10.1007/s00261-019-01994-5 · Cited by 13
Radiolabelled CCK2R Antagonists Containing PEG Linkers: Design, Synthesis and Evaluation
Novak, D., Tomašič, T., Krošelj, M., Javornik, U., Plavec, J., Anderluh, M., & Peitl, P. K. (2020) · ChemMedChem · doi:10.1002/cmdc.202000392 · Cited by 13
Ahenkorah, S., Cawthorne, C., Murce, E., Deroose, C. M., Cardinaels, T., Seimbille, Y., Bormans, G. M., Ooms, M., & Cleeren, F. (2023) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2023.108338 · Cited by 13
Fani, M., Weingaertner, V., Peitl, P. K., Mansi, R., Gaonkar, R. H., Garnuszek, P., Mikołajczak, R., Novak, D., Simončič, U., Hubalewska–Dydejczyk, A., et al. (2020) · Pharmaceuticals · doi:10.3390/ph14010019 · Cited by 13
Chandekar, K. R., & Bal, C. S. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.06.008 · Cited by 14
Physiopathological Premises to Nuclear Medicine Imaging of Pancreatic Neuroendocrine Tumours
Cuccurullo, V., Stasio, G. D. D., & Mansi, L. (2019) · Current Radiopharmaceuticals · doi:10.2174/1874471012666190206094555 · Cited by 12
Kanellopoulos, P., Lymperis, E., Kaloudi, A., de Jong, M., Krenning, E. P., Nock, B. A., & Μάινα, Θ. (2020) · Molecules · doi:10.3390/molecules25153418 · Cited by 12
Ji, X., Chen, X., Li, K., Zhang, Z., Tang, L., Li, T., Han, F., Hong, H., & Zhang, T. (2023) · Chemical & Biomedical Imaging · doi:10.1021/cbmi.3c00093 · Cited by 11
Somatostatin Receptor Subtype-2 Targeting System for Specific Delivery of Temozolomide
AghaAmiri, S., Ghosh, S. C., Vargas, S. H., Halperin, D. M., & Azhdarinia, A. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00223 · Cited by 11
Approaching Gallium-68 radiopharmaceuticals for tumor diagnosis: a Medicinal Chemist's perspective
Musumeci, F., Fasce, A., Falesiedi, M., Oleari, F., Grossi, G., Carbone, A., & Schenone, S. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117760 · Cited by 12
Salvatore, B., Caprio, M. G., Hill, B. S., Sarnella, A., Roviello, G. N., & Zannetti, A. (2019) · Cancers · doi:10.3390/cancers11101614 · Cited by 11
Behnammanesh, H., Jokar, S., Erfani, M., Geramifar, P., Sabzevari, O., Amini, M., Mazidi, S. M., Hajiramezanali, M., & Beiki, D. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103381 · Cited by 11
Wang, Y., Xu, Y., Kan, Y., Wang, W., & Yang, J. (2021) · Contrast Media & Molecular Imaging · doi:10.1155/2021/5333366 · Cited by 11
Molecular simulations of SSTR2 dynamics and interaction with ligands
Gervasoni, S. I., Guccione, C., Fanti, V., Bosin, A., Cappellini, G., Golosio, B., Ruggerone, P., & Malloci, G. (2023) · Scientific Reports · doi:10.1038/s41598-023-31823-1 · Cited by 11
PET/MR Imaging of the Pancreas
Mallak, N., Hope, T. A., & Guimarães, A. R. (2018) · Magnetic Resonance Imaging Clinics of North America · doi:10.1016/j.mric.2018.03.003 · Cited by 10
Molecular imaging and radionuclide therapy of neuroendocrine tumors
Haider, M., Al‐Toubah, T., El-Haddad, G. E., & Strosberg, J. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000519 · Cited by 10
Gaonkar, R. H., Wiesmann, F., Pozzo, L. D., McDougall, L., Zanger, S., Mikołajczak, R., Mansi, R., & Fani, M. (2021) · Pharmaceuticals · doi:10.3390/ph14040300 · Cited by 11
Ullrich, M., Wodtke, R., Brandt, F., Freudenberg, R., Kotzerke, J., Richter, S., Kopka, K., & Pietzsch, J. (2024) · Theranostics · doi:10.7150/thno.100091 · Cited by 11
Kashyap, R. K., Alipour, R., Boehm, E., Jewell, K. E., Ravikumar, A., Cardin, A., Saghebi, J., Hofman, M. S., Fahey, M. T., Michael, M., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07235-w · Cited by 9
Koustoulidou, S., Handula, M., de Ridder, C., Stuurman, D. C., Beekman, S., de Jong, M., Nonnekens, J., & Seimbille, Y. (2022) · Pharmaceuticals · doi:10.3390/ph15091155 · Cited by 9
Gabiache, G., Zadro, C., Rozenblum, L., Vezzosi, D., Mouly, C., Thoulouzan, M., Guimbaud, R., Otal, P., Dierickx, L., Rousseau, H., et al. (2023) · Cancers · doi:10.3390/cancers15184666 · Cited by 8
Carollo, A., Papi, S., Grana, C. M., Mansi, L., & Chinol, M. (2019) · Current Radiopharmaceuticals · doi:10.2174/1874471012666190306104450 · Cited by 9
Virgolini, I. J., Bahri, S., Kjær, A., Grønbæk, H., Iversen, P., Carlsen, E. A., Loft, M. D., Knigge, U., Maffey-Steffan, J., Powell, C., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.261936 · Cited by 9
Synthesis of 68Ga-Labeled cNGR-Based Glycopeptides and In Vivo Evaluation by PET Imaging
Gyuricza, B., Szabó, J. P., Arató, V., Dénes, N., Szűcs, Á., Berta, K., Kis, A., Szücs, D., Forgács, V., Szikra, D., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122103 · Cited by 9
[ 68 Ga]-Dota Peptide PET/CT in Neuroendocrine Tumors: Main Clinical Applications
Giovannini, E., Giovacchini, G., Borsò, E., Lazzeri, P., Riondato, M., Leoncini, R., Duce, V., & Ciarmiello, A. (2018) · Current Radiopharmaceuticals · doi:10.2174/1874471012666181212101244 · Cited by 10
Mavroeidi, I. A., Romanowicz, A., Haake, T., Wienker, J., Metzenmacher, M., Darwiche, K., Öezkan, F., Bölükbas, S., Stuschke, M., Umutlu, L., et al. (2024) · Theranostics · doi:10.7150/thno.98819 · Cited by 8
PET imaging of 52Mn labeled DOTATATE and DOTAJR11
Omweri, J. M., Houson, H. A., Lynch, S. E., Tekin, V., Sorace, A. G., & Lapi, S. E. (2025) · Scientific Reports · doi:10.1038/s41598-025-85143-7 · Cited by 8
Perrone, E., Calcagni, M. L., Leccisotti, L., Moretti, R., Ghai, K., Eismant, A., Parkar, T., Greifenstein, L., & Baum, R. P. (2025) · Cancers · doi:10.3390/cancers17183070 · Cited by 8
Xijing, L., & Cheng, B. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109240 · Cited by 8
Virgolini, I. J., di Santo, G., & Santo, G. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07750-w · Cited by 8
Nikhar, S., Jahan, A., Mahato, T., & Giri, A. S. (2026) · ACS Applied Nano Materials · doi:10.1021/acsanm.5c05449 · Cited by 8
Complementary Molecular and Metabolic Characterization of Meningiomas With DOTATATE and FDG-PET
Dressen, M. S., Muthukrishnan, A., Tragon, T. R., Lieberman, F. S., & Mountz, J. M. (2018) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002328 · Cited by 8
Late Effects of Parasellar Lesion Treatment: Hypogonadism and Infertility
Sbardella, E., Minnetti, M., Pofi, R., Cozzolino, A., Greco, E., Gianfrilli, D., & Isidori, A. M. (2020) · Neuroendocrinology · doi:10.1159/000508107 · Cited by 8
c-MET inhibition: novel treatment for sporadic and MEN1-associated GEP NETs
Lee, M. E., Tepede, A., Mandl, A., Weinstein, L. S., Rivero, J. D., Agarwal, S. K., & Blau, J. E. (2020) · Journal of Molecular Endocrinology · doi:10.1530/jme-20-0020 · Cited by 9
Miller, C., Klyuzhin, I. S., Chaussé, G., Brosch-Lenz, J., Koniar, H., Shi, K., Rahmim, A., & Uribe, C. (2024) · EJNMMI Physics · doi:10.1186/s40658-024-00700-9 · Cited by 7
Sakellis, C. G., & Jacene, H. A. (2024) · PET Clinics · doi:10.1016/j.cpet.2024.03.008 · Cited by 7
Optimisation of radioligand therapy in neuroendocrine tumours: Current and evolving evidence
Navalkissoor, S., Gnanasegaran, G., & Grossman, A. B. (2022) · Journal of Neuroendocrinology · doi:10.1111/jne.13208 · Cited by 7
Somatostatin Receptor Imaging PET in Neuroendocrine Neoplasm
Johnbeck, C. B., & Mortensen, J. (2021) · PET Clinics · doi:10.1016/j.cpet.2020.12.011 · Cited by 7
Li, J., Wen, X., Reszegi, R. R., Kamalrhaj, H., Parak, W. J., Chen, X. S., & Zhang, J. (2025) · 癌症：英文版 · doi:10.1002/cac2.70063 · Cited by 6
Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade
Al‐Toubah, T., Strosberg, J., Johnson, J. E. H., & El-Haddad, G. E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1187870 · Cited by 6
Borie, A. M., Dromard, Y., Chakraborty, P., Fontanaud, P., André, E. M., François, A., Colson, P. H., Muscatelli, F., Guillon, G., Desarménien, M. G., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101781 · Cited by 6
Chen, Z., Fu, H., Wu, H., Huang, J., Yao, L., Zhang, X., & Li, Y. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200424101936 · Cited by 6
Stasio, G. D. D., Buonomano, P., Travaini, L. L., Grana, C. M., & Mansi, L. (2021) · Cancers · doi:10.3390/cancers13143474 · Cited by 6
Fang, J., Wang, X., Meng, L., Zhang, J., Zhuang, R., Li, Y., Zhang, X., & Guo, Z. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00398 · Cited by 7
Improvements and future perspective in diagnostic tools for neuroendocrine neoplasms
Massironi, S., Franchina, M., Ippolito, D., Elisei, F., Falco, O., Maino, C., Pagni, F., Elvevi, A., Guerra, L., & Invernizzi, P. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2363537 · Cited by 5
Zhuo, L., Yang, X., Liao, W., Wang, J., Wang, H., Lv, M., Wang, G., Song, H., Feng, Y., Chen, Y., et al. (2019) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-018-6396-x · Cited by 5
Theranostics: Cancer imaging and therapy using injectable radionuclide-labeled ligands
Redfern, J. S. (2020) · Pharmacy & Pharmacology International Journal · doi:10.15406/ppij.2020.08.00313 · Cited by 5
Ermert, J., Benešová, M., Hugenberg, V., Gupta, V., Spahn, I., Pietzsch, H., Liolios, C. C., & Kopka, K. (2020) · Springer eBooks · doi:10.1007/978-3-030-39457-8_2 · Cited by 5
Marlin, A., Hierlmeier, I., Guillou, A., Bartholomä, M. D., Tripier, R., & Patinec, V. (2022) · Metallomics · doi:10.1093/mtomcs/mfac036 · Cited by 5
Shelar, S. B., Barick, K. C., Dutta, B., Basu, M., & Hassan, P. A. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104381 · Cited by 7
PET/MRI for Gastrointestinal Imaging
Fraum, T. J., Ludwig, D. R., Hope, T. A., & Fowler, K. J. (2018) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2018.04.011 · Cited by 5
68Ga Extemporaneous Preparations in Radiopharmacy
Rizzello, M., Pacelli, A., Bari, M. D. D., Cutrignelli, A., Iacobazzi, R. M., Lopalco, A., & Denora, N. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17070802 · Cited by 4
Chang, M., Chen, C.-T., Chiang, P.-F., Tang, I.-C., Peng, C., Wang, Y., Tai, Y., & Chiang, Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146565 · Cited by 4
Baberwal, P., & Basu, S. K. (2025) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2025.2589524 · Cited by 4
Shekhda, K. M., & Navalkissoor, S. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.07.002 · Cited by 4
Chen, Z., Mu, X., Zhang, L., Jie, Z., Tudi, K., Liang, H., Liu, Q., Li, J., Chong, W., Mo, Y., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07474-x · Cited by 4
Peptide receptor radionuclide therapy for neuroendocrine tumours
Yusuf, S., Alsadik, S., & AL-NAHHAS, A. M. (2018) · Clinical and Translational Imaging · doi:10.1007/s40336-018-0267-x · Cited by 4
Radiolabeled somatostatin analogs for cancer treatment. Review
Тищенко, В. К., Петриев, В. М., Крылов, В. В., Власова, О. П., Шегай, П. В., Иванов, С. А., & Каприн, А. Д. (2022) · Radiation and Risk Bulletin of the National Radiation and Epidemiological Registry · doi:10.21870/0131-3878-2022-31-2-76-96 · Cited by 4
Advancements of molecular imaging and radiomics in pancreatic carcinoma
Pang, X., Xie, L., Yao, W.-J., Liu, X., Pan, B., & Chen, N. (2023) · World Journal of Radiology · doi:10.4329/wjr.v15.i1.10 · Cited by 4
Peptides as Vectors for Radiopharmaceutical Therapy
Davis, R. A., Ganguly, T., Hausner, S. H., & Sutcliffe-Goulden, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-39005-0_13 · Cited by 4
Imaging inflammation in atherosclerosis: Exploring all avenues
Haider, A., Bengs, S., & Gebhard, C. (2020) · Journal of Nuclear Cardiology · doi:10.1007/s12350-020-02103-6 · Cited by 4
Liu, M., Zhang, Y., Yan, X., Zhang, H., Ren, C., Huang, Z., Cheng, Y., Xu, Q., Li, Y., Jia, R., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07484-9 · Cited by 3
Imaging Biomarkers in Radiotherapy
Zheng, D., Naqa, I. E., Qi, X. S., Sethi, A., & Alongi, F. (2026) · Cancers · doi:10.3390/cancers18081232 · Cited by 3
Deroose, C. M., Ambrosini, V., Hofland, J., Kaltsas, G., Kjær, A., Lamarca, Á., Sowa-Staszczak, A., Janson, E. T., & Fazio, N. (2026) · Journal of Neuroendocrinology · doi:10.1111/jne.70220 · Cited by 3
Radiolabeled peptides and their expanding role in clinical imaging and targeted cancer therapy
Aloj, L., Mansi, R., Luca, S. D., Accardo, A., Tesauro, D., & Morelli, G. (2024) · Journal of Peptide Science · doi:10.1002/psc.3607 · Cited by 3
Xing, H., Zhu, W., Cheng, Y., Yang, Q., Jia, R., Zhao, H., Bai, C., Huo, L., & Wu, W. (2022) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000101 · Cited by 3
Opalińska, M., Ležaić, L., Decristoforo, C., Peitl, P. K., Mikołajczak, R., Studen, A., Simončič, U., Virgolini, I. J., Trofimiuk–Müldner, M., Garnuszek, P., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06335-9 · Cited by 3
Yu, X., Yang, X., Nie, H., Jiang, W., He, X., & Ou, C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1255809 · Cited by 3
Cai, K., Zhu, Y., Zheng, Y., Wang, H., & Qian, Y. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00155 · Cited by 3
Stellenwert der Peptid-Radio-Rezeptor-Therapie für das Management neuroendokriner Tumoren
Ciuciulkaite, I., Herrmann, K., & Lahner, H. (2025) · Die Radiologie · doi:10.1007/s00117-025-01452-y · Cited by 3
Behnammanesh, H., Erfani, M., Hajiramezanali, M., Jokar, S., Geramifar, P., Sabzevari, O., Amini, M., Mazidi, S. M., & Beiki, D. (2020) · PubMed Central · doi:10.22038/aojnmb.2020.44432.1299 · Cited by 3
Pan, B., Wang, S. C., Zk, C., & Zou, G. C. (2020) · Journal of Clinical Case Studies · doi:10.16966/2471-4925.194 · Cited by 3
Radioligand Theranostics in the Management of Neuroendocrine Tumors
Harris, A. G., Vinik, A. I., O’Dorisio, T. M., & O'Dorisio, M. S. (2020) · Pancreas · doi:10.1097/mpa.0000000000001546 · Cited by 3
Current Trends in Targeted Radionuclide Therapy Development
Vorontsova, M. S., Анатольевна, К. Т., Pankratov, A. A., & Каприн, А. Д. (2021) · Medical Radiology and radiation safety · doi:10.12737/1024-6177-2021-66-6-63-70 · Cited by 3
Internalization of somatostatin receptors in brain and periphery
Csaba, Z., & Dournaud, P. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.09.004 · Cited by 3
Ghosh, S., Das, T., Suman, S. K., Sarma, H. D., & Dash, A. K. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200502002609 · Cited by 3
Zhu, W., Liu, M., & Huo, L. (2023) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000122 · Cited by 3
Research process of PET tracers for neuroendocrine tumors diagnosis
Bao, X. (2025) · American Journal of Nuclear Medicine and Molecular Imaging · doi:10.62347/jxly1661 · Cited by 2
Mansi, R., Bertarelli, N., Pozzo, L. D., Zanger, S., Bernabeu, T. B., Maëcke, H. R., & Fani, M. (2025) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-025-00363-6 · Cited by 2
Christensen, T. N., Langer, S. W., Dejanović, D., Gillings, N., Madsen, J., Persson, G. F., Keller, S. H., Albrecht‐Beste, E., & Fischer, B. M. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270233 · Cited by 2
68Ga-TP1580 as a novel molecular probe for HER2-positive tumor imaging using MicroPET
Zhong, J.-X., Pan, D., & Guan, Y.-X. (2022) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-022-08236-x · Cited by 2
Metadata
- Authors
- Fani, M., Nicolas, G. P., & Wild, D.
- Affiliations
- University Hospital of Basel (CH)
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2017-09
- Volume
- 58
- Issue
- Supplement 2
- Pages
- 61S-66S
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2752482655
- Cited by
- 274
- References
- 24
- Citations by year
- 2026: 15 · 2025: 31 · 2024: 27 · 2023: 38 · 2022: 21 · 2021: 36 · 2020: 39 · 2019: 37 · 2018: 24 · 2017: 5
- FWCI
- 22.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Nuclear Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- somatostatin receptor antagonists, somatostatin receptor scintigraphy, peptide receptor radionuclide therapy, neuroendocrine tumors, theranostics, 68Ga-DOTATOC, 177Lu-DOTATOC, receptor internalization, somatostatin receptor 2, radiolabeled somatostatin analogs
- MeSH terms
- Animals, Diagnostic Imaging, Humans, Isotope Labeling, Receptors, Somatostatin, Drug Discovery, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
